Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration.

Abstract	To characterize the PK/PD of biapenem (BIPM) in critically ill patients under continuous venovenous hemodiafiltration (CVVHDF), we conducted a prospective, open-label study in nine adult CVVHDF patients with acute renal failure at the Critical Care Medical Center, Hiroshima Prefectural Hospital. Plasma and filtrate samples were obtained at six time points. The concentrations of BIPM in plasma and filtrate were determined by HPLC. PK parameters were analyzed using Monte Carlo simulation with MIC data. BIPM concentrations in the plasma and CVVHDF filtrate peaked at the end of infusion, and the values were similar. The drug clearance by CVVHDF and non-CVVHDF was 1.28 +/- 0.14 and 9.05 +/- 4.05 L/h, respectively. Monte Carlo simulation showed that the more administration times, there were the higher the probability. In conclusion, a dosing regimen of 300 mg BIPM q8h had a higher probability of therapeutic efficacy than q12h in patients with severe sepsis under CVVHDF.
Authors	Hidemichi Suyama, Kazuro Ikawa, Norifumi Morikawa, Kayo Ikeda, Yoshihiro Fujiue, Shingo Morikawa, Kotaro Kaneko, Masao Kuwabara, Takao Yamanoue
Journal	The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 61 Issue 5 Pg. 303-13 (Oct 2008) ISSN: 0368-2781 [Print] Japan
PMID	19260350 (Publication Type: Journal Article)
Chemical References	Drosophila Proteins Nerve Tissue Proteins Nuclear Proteins Thienamycins Transcription Factors pros protein, Drosophila biapenem
Topics	Acute Kidney Injury (therapy) Adult Aged Critical Illness Drosophila Proteins Drug Resistance, Bacterial Female Hemodiafiltration Humans Infusions, Intravenous Male Middle Aged Monte Carlo Method Nerve Tissue Proteins Nuclear Proteins Pseudomonas aeruginosa (drug effects, isolation & purification) Sepsis (drug therapy, microbiology) Therapeutic Equivalency Thienamycins (administration & dosage, pharmacokinetics, pharmacology) Time Factors Transcription Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!